20/20 Biolabs Updates Investors on OneTest Strategy and Medicare Pathway

20/20 Biolabs, Inc. filed a Current Report on Form 8-K dated September 2, 2026, to furnish an investor presentation for a webinar held on the same date. The company provided an overview of its operations and detailed its strategy for its OneTest product, specifically focusing on the regulatory landscape for Multi-Cancer Early Detection (MCED) tests.

The filing highlights the passage of the Multi-Cancer Early Detection Screening Coverage Act on February 3, 2026. Signed by the President, this legislation establishes the first statutory pathway for Medicare coverage of MCED blood tests. Under the new law, the Centers for Medicare & Medicaid Services (CMS) is authorized to reimburse MCEDs beginning in 2028. The coverage applies to FDA-approved MCED tests deemed clinically appropriate by CMS, with an initial rollout targeting older Medicare cohorts.

The company presented data from Grail’s NHS-Galleri trial, which was released at the American Society of Clinical Oncology (ASCO) in May 2026. The presentation noted that the primary endpoint was missed, showing no drop in combined Stage III/IV cancers. Additionally, Stage I–II diagnoses rose by only 16% when added to standard screening, and the trial required two full tubes of whole blood, making serial screening impractical. The presentation framed these results as raising questions about the clinical utility of ctDNA-based approaches for broad Medicare population screening.

20/20 Biolabs outlined the composition of its OneTest product, which includes a cancer protein tumor marker panel and an inflammation-associated marker panel. The test utilizes machine learning algorithms to track biomarker velocity, with the company stating this approach allows for repeat testing every three or four months to detect rising trends that a single snapshot might miss. The filing also detailed the company's M&A strategy, stating it intends to acquire companies with annualized revenues between $2 million and $8 million that have a health and wellness customer base overlapping with 20/20 Biolabs.